Dyslipidemia with elevated lipoprotein (a)
Conditions
Interventions
Experimental group:On the basis of rosuvastatin, Xintong oral solution was combined
Control group:Suvastatin calcium tablets
Sponsors
Liaoning Provincial Health Industry Group Ben'gang General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years, no gender limit; 2. LDL-C>=3.4mmol/L; Lp(a) > 300mg/L; 3. Atherosclerotic cardiovascular disease (ASCVD) was classified as high risk according to the Chinese Adult Guidelines for the Prevention and Treatment of Dyslipidemia (2016 Revision); 4. No experimental drugs were used within 3 months before enrollment; 5. Join the study voluntarily and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with myopathy; 2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal value or have active liver disease; 3. Serum creatinine > 2 times the upper limit of normal value or on renal dialysis; 4. Patients who are allergic to drugs used in this study; 5. Mental and neurological disorders, unable to correctly express their will; 6. Pregnant patients, lactating patients and patients of childbearing age who do not take contraceptive measures; 7. Patients currently participating in clinical trials of other drugs or medical devices; 8. Those considered unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The degree of numerical change before and after lipoprotein treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood lipids; Incidence of adverse reactions;Correlation of lipoprotein changes with other indicators; | — |
Countries
China
Contacts
Public ContactLi Bing
Outcome results
None listed